Tetra Bio Pharma IncOver The Counter Market:TBPMQ
- LAST PRICE0.0000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.0000
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Time | Volume | TBPMQ |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Tetra Bio Pharma Inc | 520.0 | 0.0x | --- |
Bangi Inc | 5.6K | 0.0x | --- |
Laser Energetics Inc | 120.0 | 0.0x | --- |
Green and Hill Industries Inc | 100.0 | 0.0x | --- |
Calipharms Inc | 13.0K | 0.0x | --- |
Bioelife Corp | 10.0 | 0.0x | --- |
Company Information
Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.
Contact Information
- Headquarters
- 2316 St-Joseph Blvd.ORLEANS, ON, Canada K1C 1E8
- Phone
- 343-689-0714
- Fax
- 343-689-0716
Executives
- Independent Chairman of the Board
- Brent Norton
- Chief Executive Officer, Director, Chief Regulatory Officer
- Guy Chamberland
- Chief Financial Officer
- Leslie Auld
- Chief Operating Officer
- Graham Wood
- Senior Vice President - Commercial Strategy
- Dania Scott
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $520.00 |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 515.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.92 |
EPS | $-0.06 |
Book Value | $0.00 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
